Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357522 | 1.00 | KDM4E (0.69) | KDM4EGAAPOLBRAB9ANPC1 | |
| SCHEMBL8982554 | 0.89 | KDM4E (0.63) | KDM4EGAAPOLBRAB9ANPC1 | |
| SCHEMBL1900214 | 0.87 | RXFP1 (0.66) | KDM4EGAAPOLBCYP2C19MAPT | |
| Butyl Alcohol SCHEMBL27977357 | 0.86 | EPHX1 (0.57) | KDM4EGAAPOLBRAB9ANPC1 | |
| SCHEMBL28076357 | 0.86 | POLB (0.55) | KDM4EGAAPOLBRAB9ANPC1 | |
| SCHEMBL8332038 | 0.85 | KDM4E (0.63) | KDM4EGAAPOLBRAB9ANPC1 | |
| SCHEMBL11291466 | 0.83 | NPC1 (0.79) | KDM4EGAAPOLBRAB9ANPC1 | |
| SCHEMBL30393282 | 0.83 | KDM4E (0.82) | KDM4EGAAPOLBRAB9ANPC1 | |
| SCHEMBL1276481 | 0.83 | KDM4E (0.82) | KDM4EGAAPOLBRAB9ANPC1 | |
| SCHEMBL3925314 | 0.83 | ALDH1A1 (0.60) | KDM4EGAAPOLBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-109734747-B | Chiral iminodiphosphate and derivatives thereof | 科勒研究有限公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-4200308-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | Studiengesellschaft Kohle gGmbH (DE) | 2023-06-28 | — | — | EP | disclosed |
| CN-116348435-A | Process for preparing dimeric phosphazene-derived bronsted acids | 科勒研究非盈利有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-115397423-A | Combination therapy for the treatment of MPS1 | 增益治疗股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-109265451-B | Butyrylcholinesterase selective inhibitor and preparation method and application thereof | 中国药科大学 | 2022-07-15 | — | — | CN | disclosed |
| WO-2022073803-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | KDM4E 3321/4885GAA 521/4885POLB 3859/4885 |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | KDM4E 3321/4885GAA 521/4885POLB 3859/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | KDM4E 3321/4885GAA 521/4885POLB 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.